Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
13.97
-0.46 (-3.19%)
At close: Feb 27, 2026, 4:00 PM EST
14.05
+0.08 (0.57%)
After-hours: Feb 27, 2026, 7:58 PM EST
TNXP Employees
Tonix Pharmaceuticals Holding had 81 employees as of December 31, 2024. The number of employees decreased by 22 or -21.36% compared to the previous year.
Employees
81
Change (1Y)
-22
Growth (1Y)
-21.36%
Revenue / Employee
$127,148
Profits / Employee
-$1,224,926
Market Cap
178.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 81 | -22 | -21.36% |
| Dec 31, 2023 | 103 | -14 | -11.97% |
| Dec 31, 2022 | 117 | 44 | 60.27% |
| Dec 31, 2021 | 73 | 47 | 180.77% |
| Dec 31, 2020 | 26 | 10 | 62.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 279 |
| Fate Therapeutics | 181 |
| ProQR Therapeutics | 166 |
| Molecular Partners AG | 153 |
| Caribou Biosciences | 147 |
| Vaxart | 105 |
| Compugen | 74 |
| Acumen Pharmaceuticals | 61 |
TNXP News
- 4 days ago - Tonix Pharmaceuticals to Participate in Two Investor Conferences in March - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - GlobeNewsWire
- 7 weeks ago - Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - GlobeNewsWire
- 2 months ago - Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - GlobeNewsWire
- 3 months ago - Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications - Seeking Alpha